The results from a new study of the multi-kinase inhibitor fexagratinib in mouse models are raising hopes that the therapy ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader, more comprehensive approach to diagnosis ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Credit: Michael Vi/Shutterstock The European label for Johnson and Johnson Innovation Medicine’s (J&J) Darzalex (daratumumab) has been expanded to include patients with newly diagnosed multiple ...

Back in late 2022, GSK pulled the multiple myeloma ADC Blenrep from the U.S. market merely days after announcing a phase 3 trial flop. The British pharma is now aiming to reintroduce the drug in ...

Belantamab mafodotin-blmf (Blenrep), combined with pomalidomide (Pomalyst ... and dexamethasone (PVd) in relapsed/refractory multiple myeloma. Data from the phase 3 DREAMM-8 trial (NCT04484623), ...

Video / Jason Oxenham * Multiple myeloma, a common blood cancer, is incurable but can be survived for years with the right treatment and medicines, which have greatly improved. * New Zealanders ...